A formulation scientist at an infant nutrition company recalled the moment her team confirmed their first successful Lacto-N-Tetraose incorporation into a clinical trial batch. The production had been straightforward once the purity question was resolved, but the specification battle had taken eight months. Their target was an HMO blend that matched the oligosaccharide profile of average human milk at day three of lactation, and LNT needed to be present at a defined molar ratio relative to 2′-FL. The supplier they had been working with could meet the purity number but could not consistently deliver the structural isomer profile documentation — specifically, the confirmation that the Gal-β(1-3)-GlcNAc-β(1-3)-Gal-β(1-4)-Glc tetrasaccharide sequence was within tolerance and not contaminated with its structural near-neighbor LNnT. The two compounds are not separated by a standard HPLC assay unless the gradient and column are specifically optimized for the purpose.